50 Mg Eltrombopag Olamine Tablets

Name: 50 Mg Eltrombopag Olamine Tablets
Brand: NEETCO BIOPHARMA
Price: 800 INR
Availability: InStock

Price 800 INR/ Box

Get a Price/Quote

MOQ : 1 Box

50 Mg Eltrombopag Olamine Tablets Specification

Dosage Form
Tablet

Salt Composition
Eltrombopag Olamine 50 mg

Indication
Treatment of Thrombocytopenia in patients with chronic ITP or Hepatitis C

Enzyme Types
Non-Enzymatic (Small Molecule)

Feature
Highly effective platelet enhancer, convenient once-daily dosage

Ingredients
Eltrombopag Olamine, Excipients

Application
Oral administration for patients with low platelet count

Physical Color/Texture
Film-coated tablet, brown to tan colored

Fermentation Smell
Odorless

Storage Instructions
Store below 30C in a dry place, protected from light

Shelf Life
24 months

Pack Size
10 tablets per strip

Product Code
11694116

FDA Approval Status
Approved

Contraindications
Known hypersensitivity to Eltrombopag or any ingredient

Packaging Type
Alu-Alu blister

Intended Patient Group
Adults and pediatric patients (as directed)

Therapeutic Class
Thrombopoietin Receptor Agonist

Prescription Required
Yes

Administration Route
Oral

About 50 Mg Eltrombopag Olamine Tablets

Experience a Grand breakthrough in thrombocytopenia management with our 50 Mg Eltrombopag Olamine Tablets, available at an unbeatable price for your first-string healthcare needs. Each Alu-Alu blister strip contains 10 brown to tan, odorless film-coated tablets packed with remarkable efficacy as a thrombopoietin receptor agonist. Ideal for both adult and pediatric patients diagnosed with chronic ITP or Hepatitis C, this highly effective platelet enhancer offers the convenience of a once-daily oral dose. Reserve this hot deal today-prescription required. Packaged for purity, shelf life 24 months, and ready for prompt export from India. Distributor, exporter, supplier, trader.

Dedicated Treatment Use: Broad Patient Accessibility

50 Mg Eltrombopag Olamine Tablets are designed for the specific treatment of thrombocytopenia in chronic ITP or Hepatitis C patients. Suitable for adults and pediatric patients (as directed), these tablets deliver therapeutic results through oral administration. Their commercial applications extend to hospitals, clinics, and pharmacies seeking reliable platelet enhancement solutions for those with critically low platelet counts.

Premium Packaging & Export Excellence at Lowest Price

Each strip of Eltrombopag Olamine Tablets comes securely packed in premium Alu-Alu blister to ensure freshness and integrity. We serve major export markets across Asia, Africa, and the Middle East, with robust supply ability and efficient freight management. Distributors benefit from the lowest price guarantees, rapid delivery, and consistent product availability for commercial procurement.

FAQ's of 50 Mg Eltrombopag Olamine Tablets:

Q: How should 50 Mg Eltrombopag Olamine Tablets be administered?

A: These tablets are administered orally, typically once daily, and must be taken as directed by the prescribing physician. Dose adjustments may be needed based on therapeutic response and patient age.

Q: What conditions are these tablets prescribed for?

A: Eltrombopag Olamine Tablets are indicated for the treatment of thrombocytopenia in adults and pediatric patients with chronic immune thrombocytopenia (ITP) or chronic Hepatitis C.

Q: When is it contraindicated to use Eltrombopag Olamine Tablets?

A: These tablets should not be used in patients with known hypersensitivity to Eltrombopag or any of its ingredients. Always consult a healthcare provider before initiating therapy.

Q: Where can I reserve or purchase these tablets at a hot deal?

A: You can reserve or purchase 50 Mg Eltrombopag Olamine Tablets through authorized distributors, exporters, suppliers, and traders in India, often at unbeatable prices.

Q: What are the benefits of using this platelet enhancer for patients?

A: This medication offers grand efficacy in safely boosting platelet production for eligible patients, providing significant improvement in platelet count and reducing complications associated with thrombocytopenia.